Study of RO6807952 in Patients With Diabetes Mellitus Type 2

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of RO6807952 in Type 2 Diabetic Patients Inadequately Controlled With Metformin Alone

This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone. Patients will be randomized to receive doses of RO6807952, placebo, or liraglutide. The anticipated time on study treatment is 12 weeks.

Inclusion Criteria:

• Adult patients >/= 18 and </=70 years of age
• Diagnosis of diabetes mellitus, type 2 for at least 3 months
• Treated with a stable dose of metformin
• Hemoglobin A1c >/=7.0% and </=10.5% at screening
• Fasting plasma glucose </=240 mg/dL at screening
• Body mass index >/=27 kg/m2 and </=42 kg/m2 at screening
• Willing and able to maintain existing diet and exercise habits throughout the study
• C-peptide >1.5 ng/mL at screening

Exclusion Criteria:

• History of significant liver or kidney disease
• History of uncontrolled hypertension
• History of significant cardiovascular disease
• History of significant diabetic complications
• History of significant gastrointestinal conditions
• History of weight loss surgery or procedures involving the gastrointestinal tract
• History of chronic or acute pancreatitis